• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    METHOD FOR OBTAINING AMINOETHANOL DERIVATIVES of the general formula OH RjO H-CH2-CH-B R20 where R is t-butyl, cyclobutyl, 1-methylcyclobutyl; R is hydrogen or is 2 R is a radical of the general formula: 0., -: n. N-dn where R is hydrogen or alkyl R is hydrogen or alkyl, and if R-j is hydrogen, then R is hydrogen, if R is alkyl, then R. is hydrogen or alkyl, go to their salts, jeM, that is a compound of the general formula
    公开号:SU1128830A3
    申请号:SU813308249
    申请日:1981-07-08
    公开日:1984-12-07
    发明作者:Агне Торстен Олссон Отто；Аке Свенссон Лейф；Ингвар Леопольд Веттерлин Кйелл
    申请人:Актиеболагет Драко (Фирма)；
    IPC主号:
    专利说明:

    tert.butylaminoacetophenrel in 50 ml of methanol is hydrogenated at room temperature and a pressure of 345 kPa for 18 hours in the presence of 0.1 g of a palladium catalyst on carbon (10% Pd) .; The catalyst is filtered and the filtrate is evaporated to dryness. The residue is dissolved in isopropanol and diethyl ether is added to the solution to precipitate the desired product. 10
    Output 0.18 g. Purity according to liquid chromatography under pressure of 98.4%.,
    NMR spectrum, 8 ppm: 1.2 (6H, t); 1.5 (9H, s); 3.3 (6H, m); 5.3 (1H, G, 5 6.1 (2H, t); 6.9 (3N, m) (CDClj, TMS)
    PRI me R 4. Obtaining sulfate (3, 5 - (S, N-dimethylcarbamoyloxy) feNil -2-cyclobutylaminoethanol ..20
    A solution of 2.9 g of bis3 hydrochloride, 5- (K, M-dimethylcarbamoyloxy) -2 (N-benzylcyclobutyl) amino acetophenone in 50 ml of ethanol is hydrogenated at 45 ° C and a pressure of 345 kPa in the presence of 25.5 g of a palladium catalyst on carbon (10% Pd). The catalyst is filtered and the filtrate is evaporated. The resulting oil is dissolved in water, made alkaline with a .1 M solution of sodium carbonate and extracted with simple diethyl ether. The resulting evaporation was dissolved in ethanol and dissolved to pH 5.5 by the addition of ethanolic sulfuric acid. After evaporation, a crystalline residue is obtained, which is recrystallized from isopropanol. Output 1g.
    NMR spectrum, & ohm .: 2.05 (6H, m); 3.00 (14H, m); 3.65 (1H, m); 4.60 o (DOH); 4.95 (1H, m); 6.95 (3N, m) (D, 0).
    Example 5. Obtaining hydrochloride (3, (S, N-dimethylcar-, 45 bamoyloxy) phenyl -2- (1-methyl) -cyclobutylaminoethanol.
    A solution of 6 g of hydrochloride So with-3, 5 - (S, H-dimethylcarbamoyloxy) -2-Nbenzyl- (1-methyl) -cyclobutylamino-50 tofenone in 100 ml of Ethanol is hydrogenated at 45 C and a pressure of 380 kPa for 18 h in the presence of 0.5 g of palladium catalyst on carbon (10% Pd). The catalyst is filtered, the filtrate is evaporated 55 to dryness and the residue is crystallized from isopropanol and diethyl simple. . the ether.
    Output 4.3 g. The purity according to liquid chromatography under a pressure of 98.9%.
    (Found%: C18.4
    Calculated,%: C1 8.5.
    NMR spectrum (D20), S ppm: 1.50 (ZN, s); 2.10 (6H, m); 3.08 (14H, 4.70 (DOR); 5.08 (1H, m); 7.08 (ZN, m).
    Example 6. Preparation of hydrochloride (3,, N-dimethylcarbamoyl) phenyl -2-tert-butylaminoethanol.
    To a solution of 4.6 g (0.01 mol) of 5 s, 5 - (S, L-dimethylcarbamoyloxy) -2 (N-bexyl-tert-butyl) -amino-acetophenone in 100 ml of dioxane is added a solution of 0.4. g (0.01 mol) of sodium borane in water. The mixture is stirred at room temperature for 3 hours and evaporated. The oily residue is dissolved in diethyl ether and washed with water. The ether phase is dried over magnesium sulphate and evaporated. The resulting oil is dissolved in isopropanol and acidified with isopropanol hydrochloric acid. After addition of diethyl ether, 3.2 g of the hydrochloride (3., 5 -N, N-dimethylcarbamoyloxyl) -phenyl -2- (N-benzyl butyl butyl) aminoethanol are obtained, which is subjected to catalytic hydrogenation according to Example 1. The resulting desired product has the same characteristic as the product of example 1.
    Example 7. Preparation of 1 - 5-as- (3, 5-S, L-dimethylcarbamoyloxy) -phenylT-2-tert butylamino-ethanol hydrochloride.
    Example 6 is repeated, with the difference that sodium is subjected to borane reduction to 5 and C-3, 5 - (S, N-dimethylcarbamoyloxy) -2- (TreT butyl) aminoacetophenone, and sodium borane is used in an amount of 0.24 g (0.006 mol). specified acetophenone - in the amount of 2.76. g (0,006 mol). The resulting product (1.5 g) has the same characteristic as the product of example 1.
    Example 8, analogously to example 1, receive - (3, -N-ethylcarbamoyloxy) -phenyl -2-tert butylaminoethanol.
    Pharmacological testing.
    I. The test compounds were dissolved in 8 ml of distilled water and given orally to dogs weighing 1318 kg using tube G followed by giving 8 ml of water. The night before the start of the experiment, the dogs were not given a bark. Blood was taken from the saphenous vein of the anterior leg with a vacuum tube. An esterase inhibitor diisopropyl fluorophosphate was added to the blood, the samples were centrifuged with the following determination of terbutaline in the plasma. The content of terbutaline in serum indicates the degree of bronchospasm of the lytic activity of the studied compounds (the studied compounds that are esters of terbutaline indicated in the commercial product, are hydrolyzed to terbutaline in plasma). The test compounds were given in an amount providing terbutaline in serum of at least 2 ng / ml. This content must be maintained for at least 6 hours in order to provide an effective bronchospasmolytic activity. As a comparison, the known ones were used; Compounds 1- (3,5-dioxyphenyl) -2-tert-butylamino-ethanol (commercial product terbutaline, comparison .1) and 1- (3, 5-dipipaloyloxyphenyl) 2-tert., butylamino-ethanol (comparison For each test compound was determined by the period effective bronchospasmolytic activity. The studied compounds and the results of the experiments are given below. Term of effective bron B The researched hostpolytic activity of the compound, h: Example 1 5 C Comparison 1 2 II. The test compounds were dissolved in 8 ml of distilled water and orally given to soy bears weighing 1318 kg using a tube with a fresh dacha of 8 ml of water. The test compounds were given in doses that provide bronchospasmolytic activity. and after giving the tested compounds, the heart rate per minute was measured.After giving the tested compounds, an increase in the heart rate was observed and the time was determined after which the increase in the heart rate was less than 10 bie rd minute. The longer the duration of the heart rate, the longer the active period of the connection. In this experiment, the compound of Example 4 and the above known compounds were used. The following results were obtained The time under study through which the connection of the heart rate frequency is less than 10 beats in the minurimer 4 is equal to 1 2 Comparison of the data shows that the proposed compounds have a longer period of ronchospasmolytic activity known.
    权利要求:
    Claims (1)
    [1]
    METHOD FOR PRODUCING AMINOETHANOL DERIVATIVES of the general formula where R is tert-butyl, cyclobutyl,
    1-methylcyclobutyl;
    R. - hydrogen or matters
    Ϊ · * 2 "
    Rg is a radical of the general formula wherein R ^ is hydrogen or alkyl C, -C ^;
    Id is hydrogen or C ^ -Gj alkyl, and if Rj is hydrogen, then R 4 is hydrogen, if R ^ is C ^ -C ^ alkyl, then R 4 is hydrogen or C ^ -C ^ alkyl, go their salts, o Comparing j-that the compound of General formula
    m
    In 2 (К where R, R ^ and Rg have the indicated meanings; R ^ is hydrogen or a protecting group such as benzyl, and if R j is hydrogen, the hydroxyl group may be protected by a group such as Cf-Cg alkyl or benzyl, is subjected to reduction with sodium borane or hydrogen in the presence of a palladium catalyst, followed by, if necessary, deprotection and isolation of the target product as a free compound or as a salt.
    Priority by signs: 09.07.80 with R - tert. Butyl; 05.23.81 with R - cyclobutyl,
    1-methylcyclobutyl. v
    SU, m 1128830
    1128830 1
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1128830A3|1984-12-07|Method of obtaining aminoethanol derivatives or their salts
    AU662382B2|1995-08-31|Novel arylcycloalkyl derivatives their production and their use
    US6159988A|2000-12-12|Arylcycloalkyl derivatives, their production and their use
    SU606549A3|1978-05-05|Method of preparing phenylalkylamines or salts thereof
    SU1327787A3|1987-07-30|Method of producing cis,endo-2-azabicyclo-|-octane-3-carboxylic acids or acid-additive salts thereof
    HU192868B|1987-07-28|Process for producing particularly antiasthmatic medicine preparations
    US4450292A|1984-05-22|Derivatives of phenyl aliphatic carboxylic acids, and use thereof in treating gastric and gastro-duodenal ailments
    US4136197A|1979-01-23|Hypoglycaemically and hypolipidaemically effective n-substituted carboxylic acid amides
    SU670214A3|1979-06-25|Method of producing derivatives of amino acids, salts, racemates or optically active antipodes thereof
    US3687967A|1972-08-29|{60 -dehydrobiotin synthesis
    US3700692A|1972-10-24|1-|-phenyl)-1-hydroxy-2-aralkylaminoethanes
    SU845777A3|1981-07-07|Method of preparing cis-4a-phenyl-2,3,4a,5,6,7,7a-octahydro-1h-2-pyridines
    US4025644A|1977-05-24|Tyrosine derivatives and use
    Yamato et al.1981|Synthesis and structure-activity relationship of spiro [isochromanpiperidine] analogs for inhibition of histamine release. 1
    RU2037494C1|1995-06-19|Derivatives of 2-azabicyclo-[2,2,1]-hept-5-ene-2-acetic acid
    SU440826A1|1974-08-25|METHOD OF OBTAINING AMINO KETONES
    SU1128831A3|1984-12-07|Method of obtaining aminoethanol derivatives or their salts
    SU1391497A3|1988-04-23|Method of producing pyrrolidinones
    US4537906A|1985-08-27|Substituted phenylalkenoic acids and esters
    US3641097A|1972-02-08|Preparation of phenylalanine derivatives and novel intermediates
    SU503508A3|1976-02-15|The method of obtaining-bis / -oxy-aryl ethyl diaminoalkanes
    US4259257A|1981-03-31|1-Phenyl-2-amino-1,3-propanediol-N-aryloxyalkyl derivatives
    US4012528A|1977-03-15|α-AMINOALKYL-3-|-4-HYDROXY-BENZYL ALCOHOLS HAVING β-ADRENERGIC STIMULANT ACTIVITY
    US3079302A|1963-02-26|O[n-di-|carbamoyl] serine
    Vernsten et al.1953|The Preparation of Some N-Carbethoxyamino Acids
    同族专利:
    公开号 | 公开日
    FI73666B|1987-07-31|
    ES503768A0|1982-11-01|
    IE811522L|1982-01-09|
    IE51373B1|1986-12-10|
    DD202001A5|1983-08-24|
    KR850000301B1|1985-03-18|
    PL128513B1|1984-02-29|
    MY8700026A|1987-12-31|
    MX9203239A|1992-07-01|
    CA1180021A|1984-12-27|
    ES8304072A1|1983-02-16|
    NZ197628A|1985-07-12|
    KR830006174A|1983-09-20|
    SG79784G|1985-04-26|
    HU187611B|1986-02-28|
    IS1262B6|1987-03-27|
    DK157678B|1990-02-05|
    ES8300678A1|1982-11-01|
    EP0043807A2|1982-01-13|
    LU88304I2|1994-05-04|
    YU86483A|1983-12-31|
    CY1273A|1985-03-08|
    KR850000870B1|1985-06-22|
    DE3163871D1|1984-07-05|
    FI73666C|1987-11-09|
    PT73336B|1983-09-01|
    CS221845B2|1983-04-29|
    ES8304534A1|1983-03-01|
    YU170481A|1983-12-31|
    US4419364A|1983-12-06|
    NO152130B|1985-04-29|
    DK157678C|1990-06-18|
    KR850000871B1|1985-06-22|
    PH19447A|1986-04-18|
    FI812158L|1982-01-10|
    NO812311L|1982-01-11|
    KR850002740A|1985-05-15|
    ES513109A0|1983-03-01|
    IS2657A7|1982-01-10|
    AU7261881A|1982-01-14|
    HK5385A|1985-01-25|
    ES513108A0|1983-02-16|
    YU42116B|1988-04-30|
    DK303481A|1982-01-10|
    YU43168B|1989-04-30|
    PT73336A|1981-08-01|
    PL232108A1|1982-08-02|
    AT7689T|1984-06-15|
    EP0043807A3|1982-09-22|
    NO1996008I1|1996-06-27|
    NO152130C|1985-08-07|
    YU43169B|1989-04-30|
    EP0043807B1|1984-05-30|
    YU86383A|1983-12-31|
    KR850002741A|1985-05-15|
    HU184959B|1984-11-28|
    PH16535A|1983-11-10|
    AU539976B2|1984-10-25|
    US4451663A|1984-05-29|
    GR74291B|1984-06-21|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    SE178032C1|1961-01-01|
    DE1643488U|1949-11-28|1952-09-11|G E Hilge Fa|INCUBATOR.|
    DK85789C|1955-07-05|1958-06-30|Cilag Ag|Process for the preparation of d, 1- or 1-isopropyl-aminomethyl- -carbinol or salts thereof.|
    DE1768167U|1958-04-02|1958-06-04|Artur O Herrmann|ROAD OBSTACLES WARNING DEVICE.|
    DE1275069B|1960-02-15|1968-08-14|Boehringer Sohn Ingelheim|1- -1-hydroxy-2-isopropylaminoalkanes and processes for their preparation|
    BE622434A|1961-09-14|
    FR1324857A|1962-06-14|1963-04-19|Chemie Linz Ag|Process for the preparation of phenylethanolamine derivatives|
    GB1141606A|1965-04-12|1969-01-29|Rech S Et D Applic Scient Et M|Improvements in alkyl ethers of substituted phenylaminoethanols|
    DE1543372A1|1966-10-18|1971-04-01|Boehringer Sohn Ingelheim|Process for the preparation of o-substituted 3,4-dioxyphenylalkanolamines|
    US3937838A|1966-10-19|1976-02-10|Aktiebolaget Draco|Orally active bronchospasmolytic compounds and their preparation|
    NO132866C|1966-10-19|1976-01-21|Draco Ab|
    SE358633B|1966-10-19|1973-08-06|Draco Ab|
    US4011258A|1973-06-21|1977-03-08|Aktiebolaget Draco|Orally active bronchospasmolytic compounds|
    SE335359B|1966-10-19|1971-05-24|Draco Ab|
    FR6087M|1967-01-10|1968-06-04|
    SE369299B|1967-10-18|1974-08-19|Draco Ab|
    SE338324B|1967-12-19|1971-09-06|Haessle Ab|
    GB1298771A|1969-04-01|1972-12-06|Sterling Drug Inc|Carboxylic esters of hydroxyphenylalkanolamines|
    AT294046B|1969-07-08|1971-11-10|Chemie Linz Ag|Process for the preparation of N, N'-bis [2- -2-hydroxyethyl] -hexamethylenediamine, its optically active forms and the salts thereof|
    US3657319A|1970-05-05|1972-04-18|Smith Kline French Lab|Alpha-aminoalkyl-4-hydroxy-3-carboalkoxyaminobenzyl alcohols|
    NO126437B|1970-08-05|1973-02-05|Draco Ab|
    NL7112938A|1970-09-30|1972-04-05|
    CH550771A|1970-10-30|1974-06-28|Hoffmann La Roche|PROCESS FOR THE PRODUCTION OF PHENAETHYLAMINE DERIVATIVES.|
    US3876679A|1970-12-09|1975-04-08|Aldrich Chem Co Inc|Di-substituted phenethylcarbamic acid esters|
    FI55988C|1971-10-19|1979-11-12|Klinge Co Chem Pharm Fab|REFERENCE FOR THERAPEUTIC USE OF THERAPEUTIC THERAPEUTIC O-ACYLPHENOLETHANOLAMINER|
    FI56673C|1974-03-29|1981-02-04|Huhtamaeki Yhthymae Oy|NYTT FOERFARANDE FOER FRAMSTAELLNING AV ALFA-TERT-BYTYLAMINOMETHYL-4-HYDROXY-M-XYLEN-ALFA1 ALFA3-DIOL|
    JPS556625B2|1974-05-16|1980-02-18|
    US4063025A|1975-02-05|1977-12-13|Yamanouchi Pharmaceutical Co., Ltd.|4-Substituted amino-α-aminomethylbenzyl alcohol derivatives|
    SE7510988L|1975-10-01|1977-04-02|Draco Ab|NEW PHARMACEUTICAL ACTIVE ASSOCIATIONS|
    DE2710997C3|1977-03-14|1980-08-14|Dr. Karl Thomae Gmbh, 7950 Biberach|4-Alkoxy carbonylamino-phenylethanolamines, their production and their use as pharmaceuticals|SE8904064D0|1989-12-01|1989-12-01|Astra Ab|IMPROVED METHOD OF PREPARING AND INTERMEDIATE FOR THE MANUFACTURE OF BAMBUTEROL|
    SE9000948D0|1990-03-16|1990-03-16|Draco Ab|NEW USE|
    US5830422A|1995-06-23|1998-11-03|Ormiston Mining And Smelting Co. Ltd.|Method for production of sodium bicarbonate, sodium carbonate and ammonium sulfate from sodium sulfate|
    WO1997026871A1|1996-01-29|1997-07-31|Savor, Evelyn|Method of treating undesired uterine contractions using optically pure r- or rr-isomers of adrenergic beta-2 agonists|
    SE9604752D0|1996-12-20|1996-12-20|Astra Ab|Formulation and use|
    KR20030085658A|2002-04-30|2003-11-07|한올제약주식회사|An improved synthetic method of bambuterol|
    US7495028B2|2002-08-08|2009-02-24|Wen Tan|R-bambuterol, its preparation and therapeutic uses|
    ES2312669T3|2002-08-08|2009-03-01|Wen Tan|R-BAMBUTEROL, ITS PREPARATION AND THERAPEUTIC USES.|
    BRPI0413330A|2003-08-29|2006-10-10|Ranbaxy Lab Ltd|phosphodiesterase inhibitors type iv, pharmaceutical composition containing them and process for their preparation|
    US20070259874A1|2003-11-26|2007-11-08|Palle Venkata P|Phosphodiesterase Inhibitors|
    WO2006081986A1|2005-02-07|2006-08-10|F.Hoffmann-La Roche Ag|Bambuterol and integrin inhibitor combination|
    US7915286B2|2005-09-16|2011-03-29|Ranbaxy Laboratories Limited|Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors|
    EP1948167A1|2005-10-19|2008-07-30|Ranbaxy Laboratories, Ltd.|Compositions of phosphodiesterase type iv inhibitors|
    AU2006305619A1|2005-10-19|2007-04-26|Ranbaxy Laboratories Limited|Pharmaceutical compositions of muscarinic receptor antagonists|
    NZ574905A|2006-08-22|2011-12-22|Ranbaxy Lab Ltd|Matrix metalloproteinase inhibitors|
    WO2008035316A2|2006-09-22|2008-03-27|Ranbaxy Laboratories Limited|Phosphodiesterase inhibitors|
    EA200900472A1|2006-09-22|2009-10-30|Ранбакси Лабораторис Лимитед|PHOSPHODESTERASE INHIBITORS IV TYPE|
    US20080207659A1|2007-02-15|2008-08-28|Asit Kumar Chakraborti|Inhibitors of phosphodiesterase type 4|
    WO2008111009A1|2007-03-14|2008-09-18|Ranbaxy Laboratories Limited|Pyrazolo [3, 4-b] pyridine derivatives as phosphodiesterase inhibitors|
    SI2124944T1|2007-03-14|2012-05-31|Ranbaxy Lab Ltd|Pyrazolo?á3,4-b?åpyridine derivatives as phosphodiesterase inhibitors|
    EP2111861A1|2008-04-21|2009-10-28|Ranbaxy Laboratories Limited|Compositions of phosphodiesterase type IV inhibitors|
    EP2598493A1|2010-07-30|2013-06-05|Ranbaxy Laboratories Limited|Matrix metalloproteinase inhibitors|
    EP2619185A1|2010-09-24|2013-07-31|Ranbaxy Laboratories Limited|Matrix metalloproteinase inhibitors|
    AU2013353723B2|2012-12-03|2018-02-22|Pfizer Inc.|Novel selective androgen receptor modulators|
    WO2014108449A1|2013-01-08|2014-07-17|Atrogi Ab|A screening method, a kit, a method of treatment and a compound for use in a method of treatment|
    CN104557614B|2014-12-15|2017-01-04|广东东阳光药业有限公司|A kind of method of reducing of amine|
    CN105622461B|2016-01-29|2018-06-19|华南理工大学|A kind of compound and preparation method and application|
    CN105859589B|2016-04-05|2018-09-28|深圳市康立生生物科技有限公司|A method of preparing bambuterol impurity C|
    CN109942462B|2019-03-06|2022-01-14|宏冠生物药业有限公司|Synthesis process of bambuterol hydrochloride|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    GB8022439|1980-07-09|
    GB8116441|1981-05-29|LV930862A| LV5458A3|1980-07-09|1993-06-30|Attenuation to obtain aminoethanol derivatives or their islands|
    LTRP943A| LT2249B|1980-07-09|1993-09-06|AMINOETANOL'S ORGANIC WASTE|
    [返回顶部]